Suma
Cheaper & Alternative Brands
Same generic (Sumatriptan), same form (Nasal Spray)
Clinical Prescribing Information
Medical monograph and safety information for healthcare professionals & patients.Indications & Clinical Uses
Nomigran is a serotonin (5-HT1B/1D) receptor agonist (triptan) indicated for acute treatment of migraine with or without aura in adults.
Limitations of Use:
Use only if a clear diagnosis of migraine headache has been established.
Not indicated for the prophylactic therapy of migraine attacks.
Not indicated for the treatment of cluster headache.
Contraindications
History of coronary artery disease or coronary vasospasm
Wolff-Parkinson-White syndrome or other cardiac accessory conduction pathway disorders
History of stroke, transient ischemic attack, or hemiplegic or basilar migraine
Peripheral vascular disease
Ischemic bowel disease
Uncontrolled hypertension
Recent (within 24 hours) use of another 5 HT1 agonist (e.g., another triptan) or of an ergotamine containing medication
Concurrent or recent (past 2 weeks) use of monoamine oxidase A inhibitor
Hypersensitivity to sumatriptan (angioedema and anaphylaxis seen)
Severe hepatic impairment
Side Effects & Adverse Reactions
Common side effects: Unusual or unpleasant taste in the mouth; pain, burning, numbness, or tingling in the nose or throat; runny or stuffy nose after using the nasal medicine. Rare side effects: Anxiety, burning sensation, discomfort of the nasal cavity and throat, general feeling of illness or tiredness & vision changes.
Warnings & Precautions
Myocardial ischemia/infarction and Prinzmetal’s angina: Perform cardiac evaluation in patients with multiple cardiovascular risk factors
Arrhythmias: Discontinue Nomigran if occurs
Chest/throat/neck/jaw pain, tightness, pressure, or heaviness: Generally, not associated with Myocardial Ischemia; evaluate for coronary artery disease in patients at high risk
Cerebral hemorrhage, subarachnoid hemorrhage, and stroke: Discontinue Nomigran if occurs
Gastrointestinal ischemia and reactions, peripheral vasospastic reactions: Discontinue Nomigran if occurs
Medication overuse headache: Detoxification may be necessary
Serotonin syndrome: Discontinue Nomigran if occurs
Increase in blood pressure: Hypertensive crisis can occur
Hypersensitivity reactions: Angioedema and anaphylaxis can occur
Seizures: Use with caution in patients with epilepsy or a lowered seizure threshold
Local irritation: Burning and abnormal taste can occur
Pharmacology & Mechanism of Action
Sumatriptan is an agonist for a vascular 5‑hydroxytryptamine receptor subtype (probably a member of the 5‑HT family) having only a weak affinity for 5‑HT , 5‑HT , and 5‑HT receptors and no significant affinity (as measured using standard radioligand binding assays) or pharmacological activity at 5‑HT, 5‑HT or 5‑HT receptor subtypes or at alpha‑adrenergic or beta‑adrenergic; dopamine; dopamine; muscarinic; or benzodiazepine receptors. The vascular 5‑HT receptor subtype that sumatriptan activates is present on cranial arteries in both dog and primate, on the human basilar artery, and in the vasculature of human dura mater and mediates vasoconstriction. This action in humans correlates with the relief of migraine headache. In addition to causing vasoconstriction, experimental data from animal studies show that sumatriptan also activates 5‑HT receptors on peripheral terminals of the trigeminal nerve innervating cranial blood vessels. Such an action may also contribute to the antimigrainous effect of sumatriptan in humans.